Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PBT2 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Safety | Study duration |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in biomarkers; Change from baseline in cognitive and global function scales | Study duration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lars Lannfelt, Professor | Uppsala University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sydney | New South Wales | 2031 | Australia | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18672400 | Derived | Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sydney |
| New South Wales |
| 2077 |
| Australia |
| Adelaide | South Australia | 5011 | Australia |
| Melbourne | Victoria | 3081 | Australia |
| Melbourne | Victoria | 3101 | Australia |
| Melbourne | Victoria | 3146 | Australia |
| Melbourne | Victoria | 3199 | Australia |
| Falköping | 521 85 | Sweden |
| Kalix | 952 81 | Sweden |
| Kalmar | 391 85 | Sweden |
| Lund | 85 | Sweden |
| Malmö | 205 20 | Sweden |
| Stockholm | 112 98 | Sweden |
| Umeå | 901 85 | Sweden |
| Uppsala | 751 85 | Sweden |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided